中继治疗报告,在对HR+、HER2乳腺癌患者的人类第一人间研究中,RLY-2608为9.2个月的中位无进展存活率。 Relay Therapeutics reports 9.2-month median progression-free survival with RLY-2608 in first-in-human study for HR+, HER2- breast cancer patients.
在对PI3Kα突变,HR+,HER2-乳腺癌患者进行的首次人体研究中,Relay Therapeutics报告了RLY-2608的有希望的中间结果. Relay Therapeutics has reported promising interim results for RLY-2608 in a first-in-human study for patients with PI3Kα-mutated, HR+, HER2- breast cancer. 在重度预治疗的患者中,该药物与富尔韦斯特兰特联合使用的中位数无进展生存期为9. 2个月. The drug, combined with fulvestrant, showed a median progression-free survival of 9.2 months in heavily pre-treated patients. 该公司计划在明年启动一个关键的试验,并正在寻找利拉富格拉蒂尼布的商业化伙伴。 The company plans to initiate a pivotal trial next year and is seeking a commercialization partner for lirafugratinib. Relay的财务状况良好,预计将有6.88亿美元将业务维持到2026年。 Relay's financial position is strong, with $688 million projected to sustain operations into 2026.